Telephone coaching program may help patients achieve weight loss
1. The addition of 3 or 12 weeks of telephone coaching for individuals with suboptimal response in an online weight ...
Tag: GLP-1 agonist
TG103 injections may be effective in achieving weight reduction in patients with obesity
1. In this randomized, double-blind, placebo-controlled trial, the use of once-weekly subcutaneous TG103 resulted in significant weight reduction at 12 ...
Semaglutide improves symptoms and function in obesity-related heart failure
1. Semaglutide showed significant improvements in KCCQ-CSS score and reduction in body weight compared to placebo. 2. There were fewer ...
#VisualAbstract: Retatrutide reduces body weight by 17.5% in patients with obesity
In the phase 2 clinical trial of Eli Lilly's retatrutide, the drug showed a notable weight reduction effect, with an ...
#VisualAbstract:Oral semaglutide effectively reduces bodyweight in non-diabetic adults with obesity
1. The semaglutide 50 mg group saw a 15.1% reduction in body weight at 68 weeks compared to 2.4% in ...
High-dose oral semaglutide effectively glycemic control in patients with type 2 diabetes mellitus
1. HbA1c reduction was dose-dependent in the semaglutide group with the greatest change among patients on semaglutide 50 mg. 2. ...
Oral semaglutide effectively reduces bodyweight in non-diabetic adults with obesity
1. The semaglutide 50 mg group saw a 15.1% reduction in body weight at 68 weeks compared to 2.4% in ...
Retatrutide effectively reduces body weight in patients with obesity
1. In this randomized controlled trial, the triple-hormone-receptor agonist retatrutide was superior to placebo in reducing body weight among patients ...
Weekly semaglutide associated with reduced BMI in adolescents with obesity
1. In adolescents with obesity, semaglutide plus lifestyle intervention resulted in a significant body mass index (BMI) reduction compared to ...
Sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists improve diabetes outcomes but are not cost effective
1. For sodium-glucose cotransporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP1) receptor agonists to be used as first-line agents for type ...